Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters

Abstract

BackgroundIntratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is uncertain. A prospective, single-arm, translational study using targeted multiregion prostate biopsies was carried out to study genomic and T-cell ITH in clinically high-risk PC aiming to identify drivers and potential therapeutic strategies.Patients and methodsForty-nine men with elevated prostate-specific antigen and multiparametric-magnetic resonance imaging detected PC underwent image-guided multiregion transperineal biopsy. Seventy-nine tumour regions from 25 patients with PC underwent sequencing, analysis of mutations, copy number and neoepitopes combined with tumour infiltrating T-cell subset quantification.ResultsWe demonstrated extensive somatic nucleotide variation and somatic copy number alteration heterogeneity in high-risk PC. Overall, the mutational burden was low (0.93/Megabase), but two patients had hypermutation, with loss of mismatch repair (MMR) proteins, MSH2 and MSH6. Somatic copy number alteration burden was higher in patients with metastatic hormone-naive PC (mHNPC) than in those with high-risk localised PC (hrlPC), independent of Gleason grade. Mutations were rarely ubiquitous and mutational frequencies were similar for mHNPC and hrlPC patients. Enrichment of focal 3q26.2 and 3q21.3, regions containing putative metastasis drivers, was seen in mHNPC patients. We found evidence of parallel evolution with three separate clones containing activating mutations of β-catenin in a single patient. We demonstrated extensive intratumoural and intertumoural T-cell heterogeneity and high inflammatory infiltrate in the MMR-deficient (MMRD) patients and the patient with parallel evolution of β-catenin. Analysis of all patients with activating Wnt/β-catenin mutations demonstrated a low CD8+/FOXP3+ ratio, a potential surrogate marker of immune evasion.ConclusionsThe PROGENY (PROstate cancer GENomic heterogeneitY) study provides a diagnostic platform suitable for studying tumour ITH. Genetic aberrations in clinically high-risk PC are associated with altered patterns of immune infiltrate in tumours. Activating mutations of Wnt/β-catenin signalling pathway or MMRD could be considered as potential biomarkers for immunomodulation therapies.Clinical Trials.gov IdentifierNCT02022371

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer

“…As such, it is not clear that preclinical models are representative of the low to intermediate risk cancers included in this study . Furthermore, it is worth noting that many tissue samples analyzed as part of this trial had minimal to no tumor content because of the low‐grade nature of many of these cases, which could further impact the degree of inflammation present in the samples that were analyzed . Interestingly, our group has previously shown that there are significantly more tumor‐infiltrating lymphocytes (TIL) in the small subset of PC cases with mismatch repair deficiency, with a linear relationship between TIL density and mutational load .…”

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

“…Conceptually, heterogeneity encompasses multiple domains (e.g., spatial, temporal, and clonal) and can be applied to any measurable feature of a tumor; thus, it remains unclear exactly which molecular constituents of heterogeneity are most consequential to clinical outcomes. Previous studies of heterogeneity in other tumor types (e.g., renal, prostate, and lung) have focused primarily or exclusively on phylogenetic mutational analyses to characterize clonal heterogeneity of tumor cell content [29][30][31][32] . When performed, multiregion sequencing either for tumor cell mutations or TCR profiling has surveyed minimal numbers of regions (e.g., three to five per tumor), often in relatively small numbers of samples 31,[33][34][35] , whereas truly multi-platform analyses have effectively evaluated inter-tumoral rather than ITH 36 .…”

Has tailored, tissue‐selective tumour ablation in men with prostate cancer come of age?

“…Add to this challenge the variability in prostate cancer tumour attributesvolume, location, heterogeneity (genetic, radiological, and histological), degree of immune infiltrate, and the extent of microscopic extension, we begin to get the picture [1].…”

“…Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications I t took long time and consistent evidence to endorse the staging role of extended pelvic lymph node dissection (PLND) in prostate cancer (PCa). The poor performance of both conventional and functional imaging in identifying preoperative nodal status has contributed to making extended PLND the most accurate nodal staging procedure in PCa [1].…”

“…Extending the anatomical template by adding nearby nodal stations would further minimize the risk of missing positive lymph nodes; however, it has previously been shown that a more accurate staging (i.e. a more extended template) might come at the price of longer operating time and a higher risk of procedurerelated complications [1].…”